Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
This article was originally published in PharmAsia News
Anaphore, Inc., a La Jolla, CA, start-up with a novel platform for developing trimeric proteins called Atrimers, has partnered with Mitsubishi Tanabe Pharma Corporation to work on autoimmune diseases
You may also be interested in...
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).